Serum levels of semaphorin 4C in breast cancer – assessment of prognostic value and potential for monitoring surgical treatment response
DOI:
https://doi.org/10.2478/AMB-2024-0070Keywords:
breast cancer, serum biomarker, semaphorin 4c, surgical treatment, monitoringAbstract
Introduction. The global burden of breast cancer (BC) has encouraged cease less research in exploring novel biomarkers, aiming to optimize BC management and prognosis. Objective. To explore the prognostic value of serum SEMA4C and investigate its potential for monitoring the response to surgical treatment in patients with BC. Materials and methods. Seventy-five (75) pre-treatment patients from the Clinic of Surgery with invasive BC without any initial treatment prior to blood sample collection were included in the study.
The enzyme-linked immunosorbent assay (ELISA) method was used to measure serum levels of SEMA4C in human serum. Participants were divided based on pathological stage, nodal involvement and histological grade. Follow-up blood samples of 35 patients who
underwent surgery were collected to investigate if SEMA4C could measure the response to surgical treatment. Results. Postoperative serum levels of SEMA4C were significantly lower than preoperative levels (p p < 0.001). Regarding prognostic value, no statistically
significant difference was observed in terms of the pathological stage (p = 0.181), lymph node (LN) status (p = 0.752), and histological grade (p = 0.412). Conclusion. According to our study, serum SEMA4C levels did not differ significantly in terms of pathological stage,
LN status and histological grade. Notably, postoperative serum levels of SEMA4C were significantly decreased after surgical treatment compared to preoperative values, which underscores the potential of SEMA4C as a putative candidate biomarker for monitoring
response to therapy in patients with BC. However, additional research is mandatory to validate the role of SEMA4C in BC.
References
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 Apr 4.
Grancharova G, Aleksandrova-Yankulovska S, Draganova M, et al. Trends in incidence of main types of cancer in Bulgarian women (2010-2021). Eur J Public Health. 2023 Oct 24;33(Suppl 2):ckad160.1556.
Valerianova Z, Atanasov T. (editors). Cancer Incidence in Bulgaria, 2016 & 2017, Volume XXVI. Bulgarian National Cancer Registry. Sofia, Paradigma, 2020.
Aiyappa-Maudsley R, McLoughlin LFV, Hughes TA. Semaphorins and Their Roles in Breast Cancer: Implications for Therapy Resistance. International Journal of Molecular Sciences. 2023; 24(17):13093.
Mastrantonio R, You H, Tamagnone L. Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer. Theranostics. 2021 Jan 15;11(7):3262-3277.
Chen T, Li S, Wang L. Semaphorins in tumor microenvironment: Biological mechanisms and therapeutic progress. Int
Immunopharmacol. 2024 May 10;132:112035.
Gurrapu S, Pupo E, Franzolin G, et al. Sema4C/PlexinB2 signaling controls breast cancer cell growth, hormonal dependence and tumorigenic potential. Cell Death Differ. 2018 Jul;25(7):1259-1275.
Yang J, Zeng Z, Qiao L, et al. Semaphorin 4C Promotes Macrophage Recruitment and Angiogenesis in Breast Cancer. Mol Cancer Res. 2019 Oct;17(10):2015-2028. doi: 10.1158/1541-7786.MCR-18-0933.
Wei JC, Yang J, Liu D, et al. Tumor-associated Lymphatic Endothelial Cells Promote Lymphatic Metastasis By Highly Expressing and Secreting SEMA4C. Clin Cancer Res. 2017 Jan 1;23(1):214-224.
Li H, Li X, Xu S, et al. Semaphorin 4C accelerates disease progression and enables disease detection in breast cancer. Visualized Cancer Medicine. 2023; 4, 6.
Wang Y, Qiao L, Yang J, et al. Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study. Cancer Commun (Lond). 2021 Dec;41(12):1373-1386.
Neves Rebello Alves L, Dummer Meira D, Poppe Merigueti L, et al. Biomarkers in Breast Cancer: An Old Story with a New End. Genes (Basel). 2023 Jun 28;14(7):1364.
Alto L T, Terman J R. Semaphorins and their Signaling Mechanisms. Methods in molecular biology (Clifton, N.J.), 2017, 1493, 1–25.
Fard D, Tamagnone L. Semaphorins in health and disease. Cytokine Growth Factor Rev. 2021 Feb;57:55-63.
Jiang J, Zhang F, Wan Y, et al. Semaphorins as Potential Immune Therapeutic Targets for Cancer. Front Oncol. 2022 Jan 27;12:793805.
Franzolin G, Tamagnone L. Semaphorin Signaling in Cancer-Associated Inflammation. Int J Mol Sci. 2019 Jan 17;20(2):377.
Ahammad I. A comprehensive review of tumor proliferative and suppressive role of semaphorins and therapeutic approaches. Biophys Rev. 2020 Oct;12(5):1233-1247.
Bica C, Tirpe A, Nutu A, et al. Emerging roles and mechanisms of semaphorins activity in cancer. Life Sci. 2023 Apr 1;318:121499.
Neufeld G, Mumblat Y, Smolkin T, et al. The role of the semaphorins in cancer. Cell Adh Migr. 2016 Nov;10(6):652-674.
Yang Q, Wang Y, Lu X, et al. MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells. Oncotarget. 2015 Feb 20;6(5):3268-79.
Borges VF, Hu J, Young C, et al. Semaphorin 7a is a biomarker for recurrence in postpartum breast cancer. NPJ Breast Cancer. 2020 Oct 19;6:56.
Jiang D, Chen X, Li X et al. Expression patterns and pathogenesis of Semaphorin class 4 subfamily proteins in solid tumors. Neoplasma. 2024 Feb;71(1):1-12.
Paranthaman P, Veerappapillai S. Design of a potential Sema4A-based multi-epitope vaccine to combat triple-negative breast cancer: an immunoinformatic approach. Med Oncol. 2023 Feb 23;40(3):105.
Shafique MR, Fisher TL, Evans EE, et al. A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2021 Jul 1;27(13):3630-3640.
Ye SM, Han M, Kan CY, et al. Expression and clinical significance of Sema4C in esophageal cancer, gastric cancer and rectal cancer. Zhonghua Yi Xue Za Zhi. 2012 Jul 24;92(28):1954-8.
Wang Y, Liu J, Li J, et al. Serum semaphorin4C as an auxiliary diagnostic biomarker for breast cancer. Clin Transl Med. 2021 Aug;11(8):e480.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Ts. Popov, S. Maslyankov, A. Arabadzhiev, M. Sokolov, S. Kandilarova (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica 
